obesity

News

Representation of Ascendis Pharma technology

Novo puts $285m into monthly GLP-1 based on Ascendis tech

Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist.

News

Lilly pledges £279m to UK for biotech hub and obesity plan

Eli Lilly has said it is prepared to invest £279 million ($364 million) in the UK and work with the government to tackle serious public health challenges, including obesity.

News

Lawmaker asks FTC to probe Novo/Catalent deal

US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give Novo Nordisk control of manufacturing facilities currently operate

R&D

Weight loss gold rush: Developers vie for next blockbuster t...

Weight loss treatments are rapidly becoming a focal point for pharma R&D, driven by the commercial success of Eli Lilly and Novo Nordisk’s therapies.

News

Kristen Fortney, CEO and co-founder of BioAge Labs

Obesity drug developer BioAge raises $198m in IPO

BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of shares on offer by 40%.

News

Disparate global Wegovy prices listed at congressional hearing

Novo Nordisk CEO reticent on lowering semaglutide prices

Novo Nordisk chief executive Lars Fruergaard Jørgensen was taken to task by US lawmakers over the price of the company's semaglutide drugs for diabetes and obesity at a congressional hearin

Novo puts $285m into monthly GLP-1 based on Ascendis tech

Lilly pledges £279m to UK for biotech hub and obesity plan

Lawmaker asks FTC to probe Novo/Catalent deal

Weight loss gold rush: Developers vie for next blockbuster t...

Obesity drug developer BioAge raises $198m in IPO

Novo Nordisk CEO reticent on lowering semaglutide prices

Immunovant's thyroid eye disease drug flunks pivotal trials

Using AI-driven synthetic personas to take your insights fur...

obesity

Editor's Picks